Shanghai ZJ Bio-Tech Co Current Liabilities
The Current Liabilities of Shanghai ZJ Bio-Tech Co (688317.SS) as of Oct 11, 2026 is 56.45 M CNY. In the previous year, Current Liabilities was 188.81 M CNY — a change of -70.10% (lower).
Get this data via API
Financial Data API
Current Liabilities
56.45 MCNY
YoY
-70.10%
Last updated:
The Shanghai ZJ Bio-Tech Co Current Liabilities history
3 Years
10 Years
25 Years
Max
| YEAR | Current Liabilities | YoY |
|---|---|---|
| 56.45 MCNY | -70.10% | |
| 188.81 MCNY | -39.92% | |
| 314.25 MCNY | -41.79% | |
| 539.84 MCNY | +19.22% | |
| 452.81 MCNY | +10.14% | |
| 411.13 MCNY | +595.61% | |
| 59.10 MCNY | +26.53% | |
| 46.71 MCNY | +19.91% | |
| 38.96 MCNY | +14.05% | |
| 34.16 MCNY | -4.09% | |
| 35.61 MCNY | -47.43% | |
| 67.74 MCNY | +246.90% | |
| 19.53 MCNY | — |
Shanghai ZJ Bio-Tech Co Stock analysis
Frequently Asked Questions about Shanghai ZJ Bio-Tech Co stock
Current Liabilities of Shanghai ZJ Bio-Tech Co is 56.45 M CNY in 2025.
Current Liabilities of Shanghai ZJ Bio-Tech Co changed from 188.81 M CNY to 56.45 M CNY, representing a -70.10% change. The value is lower than the previous year.
On Eulerpool you can find the complete historical development of Current Liabilities Shanghai ZJ Bio-Tech Co since 2006 – with annual values, charts, and detailed analysis.
Current liabilities are obligations due within one year, including accounts payable, short-term debt, and accrued expenses.
Current Liabilities's CNY is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Liabilities's Shanghai ZJ Bio-Tech Co historically and in real time.
Balance Sheet — Shanghai ZJ Bio-Tech Co
All Key Metrics — Shanghai ZJ Bio-Tech Co
Valuation
Income Statement
Margins
Balance Sheet
- Total Assets
- Current Assets
- Cash & Equivalents
- Receivables
- Inventory
- Property, Plant & Equipment
- Goodwill
- Intangible Assets
- Equity
- Liabilities
- Debt
- Current Liabilities
- Long-term Debt
- Short-term Debt
- Retained Earnings
- Book Value per Share
- Tangible Book Value per Share
- Working Capital
- Investments
- Accounts Payable
- Non-Current Assets
- Short-Term Investments
- Long-Term Investments
- Net Debt
- Treasury Stock
- Minority Interest
- Deferred Tax Liabilities
- Net Tangible Assets
- Goodwill/Assets
- Intangibles/Assets
Cash Flow
- Operating Cash Flow
- Capital Expenditures
- Free Cash Flow
- FCF per Share
- Dividends Paid
- Share Buybacks
- Investing Cash Flow
- Financing Cash Flow
- CapEx / Revenue
- Cash Flow per Share
- Stock-Based Compensation
- Change in Working Capital
- Acquisitions (Net)
- Net Change in Cash
- CapEx/OCF
- FCF/Net Income
- FCF Conversion
- Cash Conversion
- Total Shareholder Payout
- CapEx/D&A
Profitability
- ROE
- ROA
- ROCE
- ROIC
- Asset Turnover
- Inventory Turnover
- Receivables Turnover
- Days Sales Outstanding
- Days Inventory Outstanding
- Days Payable Outstanding
- Cash Conversion Cycle
- CROIC
- Gross Profit/Assets
- Fixed Asset Turnover
- Equity Turnover
- Working Capital Turnover
- Payables Turnover
- Capital Intensity
- Receivables/Revenue
- Inventory/Revenue
- EBIT/Assets
Leverage
Growth
- Revenue Growth
- Revenue CAGR 3Y
- Revenue CAGR 5Y
- Revenue CAGR 10Y
- Earnings Growth
- EPS Growth
- EBIT Growth
- EBIT CAGR 3Y
- EBIT CAGR 5Y
- EBIT CAGR 10Y
- Dividend Growth
- FCF Growth
- Book Value Growth
- Earnings CAGR 3Y
- Earnings CAGR 5Y
- Earnings CAGR 10Y
- EPS CAGR 3Y
- EPS CAGR 5Y
- EBITDA Growth YoY
- EBITDA CAGR 3Y
- EBITDA CAGR 5Y
- Gross Profit Growth
- OCF Growth YoY
- Employee Growth
- Dividend CAGR 3Y
- Dividend CAGR 5Y
- Dividend CAGR 10Y
- Asset Growth
- Equity Growth
- Debt Growth
- CapEx Growth
- FCF CAGR 3Y
- FCF CAGR 5Y
- Market Cap Growth
- Share Count Growth